Protalix BioTherapeutics PLX
$ 1.65
-1.2%
Quarterly report 2024-Q3
added 11-14-2024
Protalix BioTherapeutics Financial Ratios 2011-2024 | PLX
Annual Financial Ratios Protalix BioTherapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
11.1 | -6.2 | -1.3 | -19.6 | -2.8 | -2.3 | -1.1 | -2.1 | 1.4 | -6.2 | -14.6 | -39.3 | -12.6 |
P/S |
1.4 | 2.0 | 1.0 | 2.0 | 0.9 | 1.8 | 4.7 | 6.7 | 18.5 | 12.3 | 35.1 | 13.3 | 55.0 |
EPS |
0.1 | -0.3 | -0.6 | -0.2 | -1.2 | -1.8 | -6.4 | -0.3 | 0.6 | -0.3 | -0.3 | -0.1 | 0.4 |
EV (Enterprise Value) |
120 M | 142 M | 77.8 M | 204 M | 149 M | 138 M | 143 M | 90.8 M | 90.7 M | 265 M | 458 M | 487 M | 512 M |
EBITDA per Share |
0.17 | -0.25 | -0.44 | 0.14 | -0.613 | -1.2 | -2.63 | -3.08 | -2.24 | -2.38 | -2.55 | -0.933 | -3.89 |
EV/EBITDA |
-2.1 | 45.9 | -9.7 | -4.1 | -2.7 | -2.4 | -3.6 | -9.0 | -16.3 | -47.7 | -13.2 | ||
PEG |
-0.07 | 0.05 | 0.01 | 0.48 | -0.09 | -0.03 | 0.01 | 0.01 | 0.0 | 0.93 | 0.11 | 0.3 | -0.06 |
P/B |
2.8 | -8.7 | -6.1 | -4.7 | -0.7 | -1.2 | -2.9 | -6.2 | 7.4 | -3.3 | -15.0 | -136.1 | -17.7 |
P/CF |
-70.2 | -3.7 | -3.6 | -4.9 | -2.5 | -7.3 | -8.2 | -1.9 | -3.3 | -6.2 | -12.4 | -318.9 | -15.8 |
ROE % |
24.76 | 140.29 | 456.96 | 24.13 | 25.99 | 50.03 | 272.51 | 294.92 | 533.77 | 53.85 | 103.13 | 346.08 | 140.08 |
ROA % |
9.84 | -26.76 | -37.44 | -9.60 | -40.26 | -43.28 | -118.09 | -35.70 | 59.68 | -38.16 | -24.52 | -14.76 | -70.51 |
ROCE % |
26.89 | -55.72 | -50.54 | -14.62 | -205.42 | -53.97 | -73.50 | -206.82 | -27.52 | -48.23 | -31.30 | -22.98 | -110.33 |
Current Ratio |
1.7 | 0.8 | 0.9 | 0.7 | 0.8 | 2.1 | 2.8 | 1.1 | 7.6 | 2.5 | 3.7 | 2.4 | 1.7 |
DSO |
27.5 | 30.8 | 25.9 | 19.4 | 31.4 | 50.4 | 32.6 | 27.5 | - | 45.4 | 66.3 | 15.0 | 226.8 |
DIO |
284.7 | 323.8 | 346.4 | 356.5 | 273.2 | 336.2 | 187.7 | 228.0 | 2883.5 | 268.8 | 535.1 | 181.0 | 14.7 |
DPO |
252.7 | 267.4 | 338.9 | 433.6 | 217.6 | 204.5 | 180.2 | 174.2 | 1814.5 | 159.3 | 353.3 | 236.1 | 660.9 |
Operating Cycle |
312.1 | 354.5 | 372.3 | 375.9 | 304.6 | 386.6 | 220.4 | 255.5 | 2883.5 | 314.2 | 601.4 | 196.0 | 241.5 |
Cash Conversion Cycle |
59.5 | 87.2 | 33.5 | -57.7 | 87.0 | 182.2 | 40.1 | 81.3 | 1069.0 | 154.9 | 248.1 | -40.1 | -419.4 |
All numbers in USD currency
Quarterly Financial Ratios Protalix BioTherapeutics
2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.04 | -0.03 | -0.03 | 0.29 | -0.05 | - | -0.07 | -0.11 | -0.05 | - | -0.09 | -0.25 | -0.14 | - | -0.14 | -0.13 | 0.1 | 0.02 | -0.24 | -0.52 | -0.5 | -0.4 | -0.04 | -0.06 | -0.5 | - | -0.09 | - | -0.48 | - | -0.07 | -0.11 | -0.09 | - | -0.04 | -0.05 | -0.06 | - | -0.09 | -0.07 | 0.08 | - | -0.06 | -0.07 | 0.05 | - | 0.06 | 0.11 | 0.07 | - | -0.1 | -0.16 | 0.06 |
EBITDA per Share |
- | - | - | - | -0.04 | - | -0.05 | -0.11 | -0.03 | - | -0.02 | -0.19 | -0.09 | - | -0.05 | -0.05 | 0.29 | 0.15 | -0.02 | -0.34 | -0.35 | -0.25 | -0.02 | -0.04 | - | - | -0.05 | -0.08 | -0.05 | - | -0.05 | -0.09 | -0.07 | - | -0.03 | -0.05 | -0.05 | - | -0.04 | -0.04 | -0.06 | - | -0.06 | -0.07 | -0.05 | - | -0.06 | 0.11 | -0.07 | - | -0.1 | -0.16 | - |
ROE % |
47.01 | -273.58 | -234.89 | -199.07 | -194.72 | 115.46 | -1855.91 | -3858.25 | -4204.84 | -2301.77 | -2285.36 | -297.58 | 10.42 | 25.59 | 25.18 | 13.83 | 9.49 | 25.99 | 36.68 | 41.68 | 46.67 | 50.03 | 78.58 | 107.34 | 89.81 | 238.09 | 311.31 | 345.70 | 456.22 | 268.56 | 233.43 | 125.08 | -30.55 | -136.70 | -122.29 | -72.75 | -15.11 | 38.62 | 59.95 | 66.87 | 81.24 | 62.74 | 225.95 | 367.83 | 55.24 | 51.86 | 85.90 | -43.28 | 296.43 | 105.90 | 34.03 | 52.49 | 19.37 |
ROA % |
22.61 | 12.65 | 8.76 | 4.59 | -26.08 | -18.43 | -23.46 | -22.20 | -23.79 | -20.74 | -27.28 | -28.78 | -24.50 | -10.19 | -9.55 | -10.86 | -21.81 | -40.26 | -49.79 | -50.66 | -47.44 | -43.28 | -50.23 | -57.36 | -42.89 | -97.12 | -105.98 | -99.01 | -112.83 | -32.51 | -36.44 | -31.51 | -23.52 | -15.28 | -25.49 | -31.77 | -34.35 | -27.37 | -32.44 | -27.30 | -25.53 | -14.92 | -21.88 | -23.76 | -5.48 | -2.21 | -19.34 | -29.52 | -68.19 | -53.31 | -17.13 | -26.42 | -9.75 |
ROCE % |
30.46 | 12.75 | 6.04 | -3.64 | -53.52 | -38.21 | -42.84 | -33.53 | -91.57 | -98.18 | -84.25 | -65.70 | 23.04 | 0.70 | 42.87 | -0.66 | -124.66 | -205.42 | -257.86 | -238.72 | -145.65 | -53.97 | -59.40 | -64.64 | -67.64 | -50.41 | -91.87 | -117.63 | -157.72 | -152.44 | -158.25 | -122.61 | -67.16 | -18.57 | -30.44 | -36.51 | -40.44 | -34.68 | -41.19 | -35.83 | -33.37 | -19.59 | -30.08 | -34.06 | -7.94 | -3.79 | -30.26 | -46.24 | -106.29 | -83.57 | -26.48 | -41.88 | -15.22 |
Current Ratio |
2.1 | 1.4 | 1.8 | 1.8 | 1.0 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 | 1.2 | 0.7 | 0.7 | 0.7 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 0.9 | 0.9 | 0.9 | 1.1 | 1.1 | 1.1 | 1.1 | 0.6 | 0.6 | 0.6 | 0.6 | 0.8 | 0.8 | 0.8 | 0.8 | 1.0 | 1.0 | 1.0 | 1.0 | 0.7 | 0.7 | 0.7 | 0.7 |
DSO |
31.3 | 64.5 | 57.3 | 7.0 | 28.0 | - | 34.3 | 41.3 | 26.5 | - | 29.9 | 49.2 | 26.6 | - | 16.9 | 16.6 | 14.1 | - | 30.1 | 35.0 | 41.2 | - | 650.9 | 215.1 | 64.6 | - | 20.9 | 24.7 | 38.1 | - | 13.5 | 35.8 | 46.6 | - | 156.2 | 62.0 | 99.8 | - | 73.8 | 70.9 | 27.1 | - | 83.5 | 84.3 | 44.8 | - | 34.5 | 4.9 | 32.9 | - | 110.8 | 164.1 | - |
DIO |
206.6 | 204.1 | 384.3 | 296.4 | 548.8 | - | 200.4 | 369.5 | 261.2 | - | 349.6 | 265.6 | 258.5 | - | 416.2 | 653.4 | 282.8 | - | 232.2 | 276.1 | 373.1 | - | 407.9 | 358.2 | 255.9 | - | 117.8 | 129.4 | 285.8 | - | 112.7 | 285.7 | 960.6 | - | 2359.8 | 2338.8 | 1491.4 | - | 338.4 | 379.0 | 163.8 | - | 457.5 | 550.9 | 563.7 | - | 155.7 | 112.4 | 149.2 | - | 115.7 | 192.9 | - |
DPO |
212.0 | 183.8 | 347.7 | 175.5 | 257.0 | - | 81.5 | 165.9 | 112.3 | - | 179.4 | 120.5 | 194.4 | - | 229.8 | 360.6 | 254.7 | - | 184.9 | 219.9 | 374.1 | - | 248.1 | 217.8 | 226.6 | - | 113.1 | 124.3 | 328.1 | - | 86.1 | 218.3 | 832.3 | - | 1485.0 | 1471.8 | 1687.6 | - | 200.5 | 224.6 | 103.1 | - | 302.1 | 363.8 | 494.4 | - | 203.1 | 146.6 | 356.0 | - | 2087.1 | 3478.6 | - |
Operating Cycle |
237.9 | 268.6 | 441.6 | 303.3 | 576.8 | - | 234.7 | 410.9 | 287.8 | - | 379.4 | 314.8 | 285.1 | - | 433.1 | 670.0 | 296.9 | - | 262.3 | 311.1 | 414.3 | - | 1058.8 | 573.3 | 320.6 | - | 138.7 | 154.1 | 323.9 | - | 126.2 | 321.5 | 1007.2 | - | 2516.0 | 2400.9 | 1591.2 | - | 412.2 | 449.9 | 190.9 | - | 541.0 | 635.2 | 608.4 | - | 190.3 | 117.3 | 182.2 | - | 226.5 | 357.0 | - |
Cash Conversion Cycle |
25.8 | 84.9 | 93.9 | 127.8 | 414.6 | - | 153.2 | 244.9 | 175.4 | - | 200.0 | 194.3 | 90.7 | - | 203.4 | 309.4 | 42.2 | - | 77.4 | 91.2 | 40.2 | - | 810.7 | 355.5 | 94.0 | - | 25.6 | 29.9 | -4.2 | - | 40.1 | 103.2 | 174.9 | - | 1031.0 | 929.1 | -96.5 | - | 211.7 | 225.3 | 87.8 | - | 238.9 | 271.4 | 114.1 | - | -12.8 | -29.2 | -173.8 | - | -1860.7 | -3121.6 | - |
All numbers in USD currency